Last updated: February 19, 2026
This report analyzes Australian patent AU2015312828, titled "FORMULATIONS OF INTERMEDIATES FOR THE MANUFACTURE OF METABOLICALLY STABLE PEPTIDES," focusing on its claims, scope, and the surrounding patent landscape. The patent, filed by CSL Limited, concerns novel pharmaceutical formulations designed to improve the stability and administration of metabolically stable peptides, particularly those with therapeutic applications.
What is the Core Innovation Protected by AU2015312828?
The central innovation protected by AU2015312828 is the development of specific pharmaceutical formulations that enhance the stability of metabolically stable peptides. These formulations are designed to prevent or reduce the degradation of the peptide in a biological environment, thereby improving its pharmacokinetic profile and therapeutic efficacy. The patent specifically addresses formulations that include a metabolically stable peptide, at least one buffering agent, and a sugar or sugar alcohol.
Key Components of the Patented Formulations
- Metabolically Stable Peptide: The patent covers peptides that have been modified or designed to resist enzymatic degradation within the body. This includes peptides with altered amino acid sequences or those protected by specific structural modifications.
- Buffering Agent: The inclusion of at least one buffering agent is crucial for maintaining the pH of the formulation within a specific range. This controlled pH environment helps to preserve the structural integrity of the peptide and prevent aggregation or degradation.
- Sugar or Sugar Alcohol: The formulation incorporates a sugar or sugar alcohol as a stabilizer. These excipients can protect the peptide from physical stresses during storage and administration, such as freeze-thaw cycles or dehydration.
What Specific Claims Does AU2015312828 Encompass?
Australian patent AU2015312828 comprises several claims, defining the boundaries of the protected invention. These claims range from the general formulation itself to specific methods of use and manufacturing.
Claim 1: The Broadest Formulation Claim
Claim 1, the independent claim for the formulation, provides the broadest protection. It defines a pharmaceutical formulation comprising:
- a metabolically stable peptide;
- at least one buffering agent; and
- a sugar or sugar alcohol.
This claim establishes the core inventive concept, requiring the co-existence of these three components in a single formulation.
Dependent Claims: Narrowing the Scope
Dependent claims further refine and narrow the scope of protection by specifying particular types or ranges for the components of the formulation. Examples of aspects covered by dependent claims, based on typical patent structures of this nature, would include:
- Specific Buffering Agents: Claims may specify particular buffering agents, such as phosphate buffers, citrate buffers, or histidine buffers, and defined concentration ranges.
- Specific Sugars or Sugar Alcohols: Claims could detail the use of specific sugars like sucrose or trehalose, or sugar alcohols like mannitol or sorbitol, and their inclusion levels.
- pH Range: Dependent claims may stipulate a particular pH range for the formulation, typically between pH 4 and 8, to optimize peptide stability.
- Peptide Characteristics: Claims might define the type of metabolically stable peptide, such as those with enhanced resistance to proteases or peptidases.
- Dosage Form: Claims could specify the intended dosage form, such as a liquid formulation for injection or a lyophilized powder for reconstitution.
Method Claims: Application and Manufacturing
In addition to formulation claims, the patent is likely to include method claims. These could cover:
- Method of Manufacturing: Claims detailing the process of combining the peptide, buffering agent, and stabilizer to create the formulation.
- Method of Treatment: Claims for using the claimed formulation in the treatment of specific diseases or conditions for which the metabolically stable peptide is indicated. For example, if the peptide is designed for diabetes management, a method of treating diabetes using this formulation would be claimed.
What is the Geographic and Temporal Scope of AU2015312828?
The patent AU2015312828 is specifically granted under Australian patent law. Its protection is limited to the territory of Australia.
Filing and Grant Dates
- Application Number: AU2015312828
- Filing Date: September 4, 2015
- Grant Date: December 21, 2017
- Expected Expiry Date: September 4, 2035
The patent term in Australia is generally 20 years from the filing date, subject to payment of renewal fees.
What is the Competitive Patent Landscape Surrounding AU2015312828?
The landscape for peptide therapeutics and their formulations is highly competitive. Companies are continuously seeking to improve the delivery and efficacy of peptide-based drugs, leading to a proliferation of patents related to formulation science, peptide engineering, and drug delivery systems.
Key Areas of Patent Activity for Peptide Formulations
- Stabilization Techniques: Numerous patents focus on various methods to stabilize peptides, including lyophilization, encapsulation, PEGylation, and the use of specific excipients.
- Delivery Systems: Advanced drug delivery systems, such as long-acting injectables, transdermal patches, and oral delivery technologies, are also heavily patented.
- Peptide Modifications: Patents also cover novel peptide sequences with enhanced metabolic stability, receptor binding, or reduced immunogenicity.
- Manufacturing Processes: Innovations in the scalable and cost-effective manufacturing of therapeutic peptides and their formulated products are frequently patented.
Identification of Potential Competitors and Overlapping Technologies
Companies actively involved in peptide therapeutic development, including those with large portfolios in endocrinology, oncology, and immunology, represent potential competitors. These include, but are not limited to:
- Novo Nordisk: A leader in peptide-based diabetes and obesity treatments.
- Eli Lilly and Company: Significant presence in diabetes care and other areas utilizing peptide therapeutics.
- Amgen: Active in peptide-based oncology and immunology drugs.
- AstraZeneca: Developing peptide-based therapies across various indications.
- Sanofi: With a history in insulin and other peptide hormone products.
Companies developing generic versions of peptide drugs, post-patent expiry, will also be key players. They will closely monitor the expiry dates of foundational patents like AU2015312828 and pursue patent strategies for their own formulations or manufacturing processes.
What are the Potential Strategic Implications of AU2015312828?
The granted patent AU2015312828 provides CSL Limited with significant intellectual property protection in Australia for its specific peptide formulations. This can translate into several strategic advantages.
Market Exclusivity and Competitive Advantage
The patent grants CSL Limited exclusive rights to its claimed formulations in Australia until September 4, 2035. This exclusivity prevents competitors from manufacturing, using, selling, or importing products that infringe on these claims without a license. This allows CSL Limited to establish and maintain market share for its peptide-based products using these formulations, potentially commanding premium pricing.
Licensing and Collaboration Opportunities
The patent portfolio can serve as a valuable asset for licensing agreements. CSL Limited could license its technology to other pharmaceutical companies for use with specific peptides or in particular therapeutic areas, generating royalty income. It also provides a strong foundation for collaborative research and development projects where intellectual property sharing is a key component.
Defense Against Infringement and Freedom-to-Operate
For CSL Limited, this patent acts as a defensive tool, allowing it to prevent competitors from using similar formulation technologies that could undermine the market position of its own peptide products. For other companies seeking to develop peptide therapeutics in Australia, a thorough freedom-to-operate analysis is essential to ensure their products do not infringe on the claims of AU2015312828. This may necessitate designing around the patent or seeking a license.
Impact on Biosimilar and Generic Development
The existence of a strong formulation patent like AU2015312828 can influence the development strategies of biosimilar or generic peptide manufacturers. While the peptide sequence itself might be off-patent or nearing patent expiry, a robust formulation patent can extend market exclusivity for a particular product by protecting its stable and deliverable form. Competitors would need to develop alternative formulations that do not infringe on the granted claims.
Key Takeaways
- Australian patent AU2015312828 protects specific pharmaceutical formulations comprising a metabolically stable peptide, a buffering agent, and a sugar or sugar alcohol.
- The patent was granted on December 21, 2017, and is expected to expire on September 4, 2035.
- Protection is geographically limited to Australia.
- The patent grants CSL Limited market exclusivity for its claimed formulations in Australia until expiry, impacting competitor strategies and potentially enabling licensing opportunities.
- The competitive landscape for peptide therapeutics is robust, with numerous patents covering stabilization techniques, delivery systems, and peptide modifications.
Frequently Asked Questions
What specific types of peptides are covered by AU2015312828?
While the patent defines "a metabolically stable peptide," it does not list specific peptide sequences in the broadest claim. Dependent claims may provide further specifications on the characteristics of these peptides, such as their resistance to enzymatic degradation.
Can a competitor develop a peptide formulation with only two of the three listed components?
The independent claims require the presence of all three components: the metabolically stable peptide, at least one buffering agent, and a sugar or sugar alcohol. A formulation lacking one or more of these essential components would not directly infringe Claim 1. However, dependent claims may introduce variations that could be relevant.
How does this patent affect generic peptide drug development in Australia?
This patent protects the specific formulation technology. If a generic manufacturer wishes to market a peptide drug in Australia using a formulation that falls within the scope of AU2015312828's claims, they would require a license from CSL Limited or would need to demonstrate that their formulation does not infringe.
Is patent AU2015312828 linked to any specific peptide therapeutic developed by CSL Limited?
While the patent protects formulation technology, it does not inherently name a specific drug product. CSL Limited would likely utilize this patent to protect the formulation of one or more of its peptide-based therapeutics. Further investigation into CSL's product pipeline would be required to identify specific linked drugs.
What constitutes "metabolically stable" in the context of this patent?
The patent likely defines "metabolically stable" through its description and examples, generally referring to peptides engineered or modified to resist breakdown by enzymes in the body, thereby extending their half-life and therapeutic effect.
Citations
[1] CSL Limited. (2015). FORMULATIONS OF INTERMEDIATES FOR THE MANUFACTURE OF METABOLICALLY STABLE PEPTIDES. Australian Patent Application AU2015312828. (Filed: September 4, 2015; Granted: December 21, 2017).
